Abstract
The development of microarray technology has enabled scientists to measure the expression of thousands of genes simultaneously, resulting in a surge of interest in several disciplines throughout biology and medicine. While data clustering has been used for decades in image processing and pattern recognition, in recent years it has joined this wave of activity as a popular technique to analyze microarrays. To illustrate its application to genomics, clustering applied to genes from a set of microarray data groups together those genes whose expression levels exhibit similar behavior throughout the samples, and when applied to samples it offers the potential to discriminate pathologies based on their differential patterns of gene expression. Although clustering has now been used for many years in the context of gene expression microarrays, it has remained highly problematic. The choice of a clustering algorithm and validation index is not a trivial one, more so when applying them to high throughput biological or medical data. Factors to consider when choosing an algorithm include the nature of the application, the characteristics of the objects to be analyzed, the expected number and shape of the clusters, and the complexity of the problem versus computational power available. In some cases a very simple algorithm may be appropriate to tackle a problem, but many situations may require a more complex and powerful algorithm better suited for the job at hand. In this paper, we will cover the theoretical aspects of clustering, including error and learning, followed by an overview of popular clustering algorithms and classical validation indices. We also discuss the relative performance of these algorithms and indices and conclude with examples of the application of clustering to computational biology.
Current Genomics
Title: Clustering Algorithms: On Learning, Validation, Performance, and Applications to Genomics
Volume: 10 Issue: 6
Author(s): Lori Dalton, Virginia Ballarin and Marcel Brun
Affiliation:
Abstract: The development of microarray technology has enabled scientists to measure the expression of thousands of genes simultaneously, resulting in a surge of interest in several disciplines throughout biology and medicine. While data clustering has been used for decades in image processing and pattern recognition, in recent years it has joined this wave of activity as a popular technique to analyze microarrays. To illustrate its application to genomics, clustering applied to genes from a set of microarray data groups together those genes whose expression levels exhibit similar behavior throughout the samples, and when applied to samples it offers the potential to discriminate pathologies based on their differential patterns of gene expression. Although clustering has now been used for many years in the context of gene expression microarrays, it has remained highly problematic. The choice of a clustering algorithm and validation index is not a trivial one, more so when applying them to high throughput biological or medical data. Factors to consider when choosing an algorithm include the nature of the application, the characteristics of the objects to be analyzed, the expected number and shape of the clusters, and the complexity of the problem versus computational power available. In some cases a very simple algorithm may be appropriate to tackle a problem, but many situations may require a more complex and powerful algorithm better suited for the job at hand. In this paper, we will cover the theoretical aspects of clustering, including error and learning, followed by an overview of popular clustering algorithms and classical validation indices. We also discuss the relative performance of these algorithms and indices and conclude with examples of the application of clustering to computational biology.
Export Options
About this article
Cite this article as:
Dalton Lori, Ballarin Virginia and Brun Marcel, Clustering Algorithms: On Learning, Validation, Performance, and Applications to Genomics, Current Genomics 2009; 10 (6) . https://dx.doi.org/10.2174/138920209789177601
DOI https://dx.doi.org/10.2174/138920209789177601 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets The Nitric Oxide Prodrug JS-K and Its Structural Analogues as Cancer Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer
Current Pharmaceutical Design Mitophagy in Carcinogenesis and Tumour Progression- A New Paradigm with Emerging Importance
Anti-Cancer Agents in Medicinal Chemistry Posttranscriptional Regulation of p53 and its Targets by RNABinding Proteins
Current Molecular Medicine Nano Approaches to Enhance Pharmacokinetic and Pharmacodynamic Activity of Plant Origin Drugs
Current Nanoscience Review of Noscapine and its Analogues as Potential Anti-Cancer Drugs
Mini-Reviews in Organic Chemistry Signal Transduction Pathways of Inflammatory Gene Expressions and Therapeutic Implications
Current Pharmaceutical Design Tools For Decision-Making In Older Cancer Patients. Role Of The Comprehensive Geriatric Assessment
Anti-Cancer Agents in Medicinal Chemistry Melatonin, its Metabolites and its Synthetic Analogs as Multi-Faceted Compounds: Antioxidant, Prooxidant and Inhibitor of Bioactivation Reactions
Current Medicinal Chemistry The CLCA Gene Family A Novel Family of Putative Chloride Channels
Current Genomics Immunotherapy in Gastric Carcinoma: Current Status and Future Perspectives
Clinical Cancer Drugs Chlorambucil Cytotoxicity Reduction in Rats Through Bone Marrow, An In vivo Study
Anti-Cancer Agents in Medicinal Chemistry How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease
Current Drug Targets The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
Current Pharmaceutical Design Targeted Gene Therapy for Ovarian Cancer
Current Gene Therapy Investigating ABCB1-Mediated Drug-Drug Interactions: Considerations for In vitro and In vivo Assay Design
Current Drug Metabolism Piperine: Medicinal, Analytical and Therapeutics perspective
Current Bioactive Compounds Poly(lactic acid)-poly(ethylene oxide) Block Copolymers: New Directions in Self-Assembly and Biomedical Applications
Current Medicinal Chemistry VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future
Current Cancer Drug Targets